Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigation BRANFORD, Conn., May 23, 2018 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of inflammatory bowel disease (IBD), today announced...

Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel...